Walmart shares slide as U.S. sales hit by falling drug prices

Walmart’s second-quarter report revealed a notable slowdown in its U.S. business, with comparable sales rising just 2.6%—the weakest pace in over five years. The news sent shares lower as investors weighed the implications of a maturing growth story at the world’s largest retailer.

The deceleration was attributed largely to falling drug prices. Pharmacy sales are a meaningful component of Walmart’s U.S. comparable-sales figure, and when prescription prices decline, the dollar value of those sales shrinks even if the number of prescriptions filled holds steady. This creates a price-driven headwind that depresses the headline growth number without necessarily signaling a broader drop in consumer demand.

For investors, the key question is whether this is an isolated, pharmacy-related artifact or a sign of softer spending across general merchandise. Watching how management frames the split between price effects and unit volume trends in the coming quarters will be important. The slide in Walmart’s stock suggests the market is recalibrating its expectations for near-term U.S. growth—especially with drug pricing remaining a sensitive regulatory and political issue.